Company profile: Intarcia
1.1 - Company Overview
Company description
- Provider of long-term therapies for chronic diseases, offering the MEDICITM Drug Delivery System for twice-yearly subcutaneous osmotic implants, ITCA 650 (twice-yearly exenatide implant) for type 2 diabetes, and an Ionic Liquid Platform converting injectable biologics and peptides into oral therapies; pipeline includes i2o-105s (long-acting GLP-1 receptor agonist), i2o-107 (long-acting amylin), and i2o-110 (dual agonist) for type 2 diabetes, obesity, and NASH.
Products and services
- MEDICITM Drug Delivery System: Engineers twice-yearly subcutaneous osmotic implants that deliver continuous dosing for diseases that require long-term chronic treatment
- ITCA 650: Builds a twice-yearly MediciTM implant using exenatide for type 2 diabetes, delivering therapy through implant-based administration
- Ionic Liquid Platform: Develops a platform transforming injectable biologics and peptides into oral therapies for diseases that require long-term chronic treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Intarcia
Diasome
HQ: United States
Website
- Description: Provider of insulin-based, liver-targeted diabetes therapeutics utilizing Hepatocyte Directed Vesicles (HDV) to enhance insulin delivery and reduce hypoglycemia risk. The company conducts multiple Phase 2 studies, including OPTI-2 and ISLE-1 Phase 2b trials, the Good to Great study, and an insulin pump crossover study, evaluating HDV added to rapid-acting insulin in patients with Type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diasome company profile →
Freedom Meditech
HQ: United States
Website
- Description: Provider of alternatives to existing diagnostic tools for the detection, monitoring, and management of chronic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Freedom Meditech company profile →
TypeZero
HQ: United States
Website
- Description: Provider of digital health and personalized medicine focused on the treatment and management of diabetes, leveraging more than 10 years of clinical trials, research, and innovation to develop the inControl Diabetes Management Platform to improve and simplify the lives of people with diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TypeZero company profile →
JanOne
HQ: United States
Website
- Description: Provider of pharmaceutical drug candidates targeting severe pain conditions, including JAN101, a twice-daily slow-release oral sodium nitrite formulation for treatment and prevention of peripheral artery disease (PAD) and associated pain, and Jan123, a low-dose naltrexone candidate for complex regional pain syndrome delivered via a unique oral biphasic release tablet.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JanOne company profile →
Glycostasis
HQ: United States
Website
- Description: Provider of engineered human protein technology that releases insulin when blood glucose levels rise and binds it when levels fall, mimicking the natural regulation of insulin in healthy individuals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glycostasis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Intarcia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Intarcia
2.2 - Growth funds investing in similar companies to Intarcia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Intarcia
4.2 - Public trading comparable groups for Intarcia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →